

TABLE OF CONTENTS

ILLUSTRATIONS IN THIS BOOK	IV
PSAP-VII EDITORIAL BOARD.....	V
WELCOME.....	VI
FACULTY POTENTIAL COI DISCLOSURE.....	VII
ROLE OF ACCP.....	VII
ROLE OF BPS.....	VII
CPE AND PROGRAM INSTRUCTIONS.....	VIII
POSTTEST INSTRUCTIONS.....	VIII

Women’s and Men’s Health I	1
Women’s and Men’s Health I Panel	3
Women’s and Men’s Health I Subscriber Evaluation	5

CONTROVERSIES IN WOMEN’S AND MEN’S HEALTH

By Shareen Y. El-Ibiary, Pharm.D., BCPS; and Erin C. Raney, Pharm.D., BCPS

Introduction.....	7
Emergency Contraception.....	7
Product Updates.....	7
Effectiveness.....	8
Behavior.....	9
Human Papillomavirus Vaccine.....	9
Background.....	9
Products Available.....	10
Use in Women Older than 26 Years.....	13
Use in Boys and Men.....	14
Postmenopausal HT.....	14
Trends in Product Development.....	15
Clinical Uses of Newer Products.....	15
Conclusion.....	18
Annotated Bibliography.....	18
Self Assessment Questions.....	23

SEXUALLY TRANSMITTED INFECTIONS

By Michael E. Klepser, Pharm.D., FCCP; and Jennifer K. Hagerman, Pharm.D.

Introduction.....	27
Prevention and Control of STIs.....	27
Screening in Special Populations.....	28
Pregnant Women.....	28
Adolescents.....	29
Individuals with Same-Sex Partners.....	29
Diseases Characterized by Genital Ulcers.....	29
Syphilis.....	29
Genital HSV Infections.....	30
Chancroid.....	31
Granuloma Inguinale (Donovanosis).....	32
Lymphogranuloma Venereum.....	32
Diseases Characterized by Urethritis and Cervicitis.....	32
<i>C. trachomatis</i>	32
Gonococcal Infections.....	33
Nongonococcal Urethritis.....	34

Diseases Characterized by Vaginal Discharge.....	35
Bacterial Vaginosis.....	35
Trichomoniasis.....	36
The Pharmacist’s Role in the Management of STIs.....	36
Conclusion.....	36
Annotated Bibliography.....	36
Self Assessment Questions.....	40

SPECIAL CONSIDERATIONS FOR WOMEN WITH HIV INFECTION

By Patty Fan-Havard, Pharm.D.; and Kristen Lamberjack, Pharm.D.

Introduction.....	43
Epidemiology.....	44
Mother-to-Child Transmission.....	44
Maternal Factors.....	44
Obstetric Factors.....	44
Infant Factors.....	45
ART Regimens in Reducing Perinatal HIV-1 Transmission.....	45
Experience in the United States.....	45
Breast Feeding in Resource Poor Settings.....	48
Results of International Trials.....	49
Screening, Prophylaxis, and Treatment for Pregnant Women.....	50
Antepartum Care.....	50
Pharmacokinetics of ART Regimens in Pregnancy.....	54
Transplacental Distribution of ARV Agents.....	54
Considerations of ARV Agents in Pregnancy.....	54
Intrapartum Care.....	55
Maternal Postpartum Considerations.....	55
Infant Postpartum Considerations.....	55
Testing in HIV-Exposed Infants.....	56
Safety Issues with the Use of ART in Pregnancy.....	56
Pregnancy-Related Considerations.....	56
Infant-Related Considerations.....	57
Primary Prevention of AIDS-OI During Pregnancy.....	58
<i>P. jiroveci</i> Pneumonia.....	58
<i>T. gondii</i> Encephalitis.....	58
Disseminated MAC Disease.....	58
Women’s Health Issues: Special Considerations.....	59
Age of Natural Menopause and Menopausal Symptoms.....	60
Cardiovascular Risks.....	60
Risks of Cardiovascular Disease in Patients with HIV Infection.....	61
Osteoporosis.....	62
Prevention and Management Considerations in Women with HIV Infection.....	62
Role of the Pharmacist.....	63
Conclusion.....	63
Annotated Bibliography.....	64
Self Assessment Questions.....	67

Women's and Men's Health II	71
Women's and Men's Health II Panel	73
Women's and Men's Health II Subscriber Evaluation	75

MENSTRUAL-RELATED DISORDERS

By Courtney I. Jarvis, Pharm.D.;
and Anna K. Morin, Pharm.D.

Premenstrual Syndrome/Premenstrual	
Dysphoric Disorder	77
Etiology	77
Characteristics	78
Supportive Therapies	78
Pharmacologic Treatment	79
Abnormal and Dysfunctional Uterine Bleeding	81
Pathophysiology	81
Diagnosis	82
Treatment/Management	82
Polycystic Ovary Syndrome	84
Pathophysiology	85
Clinical Findings	86
Diagnosis	86
Treatment	86
Role of the Pharmacist	88
Annotated Bibliography	88
Self Assessment Questions	91

RECENT CONTROVERSIES IN HORMONAL CONTRACEPTION

By Sarah P. Shrader, Pharm.D., BCPS, CDE;
and Kelly R. Ragucci, Pharm.D., FCCP, BCPS, CDE

Introduction	95
Combined Hormonal Contraception	95
Women Older Than 35	95
Obese Women	96
Efficacy of Low-Dose Contraceptives	97
Hormonal Intrauterine Devices	97
Infection Risk	97
Use in Adolescents and Nulliparous Women	98
Women with Fibroids	100
Depot Medroxyprogesterone Acetate and Bone Health	100
Subdermal Progestin Implant	101
Weight	101
Bone Health	101
Role of the Pharmacist	101
Conclusion	102
Annotated Bibliography	102
Self Assessment Questions	106

PRECONCEPTION CARE

By Alexander B. Guirguis, Pharm.D., BCPS

Introduction	111
Defining Preconception Care	111
Targeting Patients for Preconception Care	113
General Elements of Preconception Care	113
Nutrition/Lifestyle Recommendations	113
Infectious Diseases and Vaccinations	115

Other Screening	116
Environmental Exposure	116
Substance Use	116
Chronic Disease and Preconception Care	117
Diabetes Mellitus	117
Hypertension	118
Epilepsy	118
Conditions Requiring Antithrombotic Therapy	118
Psychiatric Disorders	119
Drug Exposure	120
Teratogenic Drugs	120
Drugs That May Increase Risk of Miscarriage or Decrease Fertility	120
Role of the Pharmacist	121
Annotated Bibliography	121
Self Assessment Questions	126

Women's and Men's Health III129

Women's and Men's Health III Panel131

Women's and Men's Health III Subscriber Evaluation132

EATING DISORDERS

By Martha P. Fankhauser, MSPharm., FASHP, BCPP

Introduction.....	135
Epidemiology.....	135
Etiology.....	136
Diagnosis	137
Diagnostic Criteria	137
Eating Disorders in Special Populations	139
Comorbid Psychiatric and Medical Conditions	139
Outcomes and Prognosis	140
Assessment and Treatment.....	140
Guidelines for Eating Disorders.....	140
Level of Care	141
Medical and Psychiatric Assessment.....	143
Nonpharmacologic Approaches	143
Pharmacologic Approaches.....	144
Role of the Pharmacist.....	146
Conclusion.....	147
Annotated Bibliography	147
Self Assessment Questions	152

SEXUAL DYSFUNCTION IN WOMEN

By Dana A. Brown, Pharm.D., BCPS

Introduction.....	157
Epidemiology	157
Female Sexual Response Cycle	157
Classification	158
Etiology	159
Pathophysiology	159
Contributing Factors	159
Drugs	160
Diagnosis	160
Medical and Drug Histories	160
Physical Examination	160
Psychosexual Assessment	160
Laboratory and Other Testing.....	161
Treatment	161

Lifestyle Management	161
Pharmacotherapy	163
Complementary Medicine	167
Medical Devices	167
Monitoring	168
Patient Education	168
Conclusion	169
Annotated Bibliography	169
Self Assessment Questions	173

UNCOMMON DISEASES IN MEN

By Justin J. Sherman, Pharm.D., MCS

Introduction	177
Osteoporosis in Men	177
Pathophysiology	178
Patient Presentation and Clinical Evaluation	179
Treatment	180
Breast Cancer in Men	181
Risk Factors	181
Pathophysiology	182
Presentation and Clinical Evaluation	182
Treatment	182
Depression in Men	183
Clinical Presentation and Evaluation	183
Hormonal Deficiencies	185
Etiology and Presentation	185
Conclusion	186
Annotated Bibliography	187
Self Assessment Questions	193

Women's and Men's Health IV197

Women's and Men's Health IV Panel199

Women's and Men's Health IV Subscriber Evaluation201

DRUG-INDUCED OSTEOPOROSIS

By Susan K. Bowles, Pharm.D., MSc, FCCP

Introduction	203
Epidemiology	203
Diagnosis	204
Risk Factors	204
Osteoporosis Related to Specific Drugs	206
Hormonal Therapies	206
Central Nervous System Agents	208
Gastric Acid-Reducing Agents	209
Thiazolidinediones	210
Summary of Drug-Induced Osteoporosis	210
Managing Drug-Induced Osteoporosis	211
Nonpharmacologic Interventions	211
Pharmacologic Interventions	211
Specific Guidelines	211
Osteoporosis Induced by GnRH Agonists in Men	212
Role of the Pharmacist	214
Conclusion	214
Annotated Bibliography	214
Self Assessment Questions	220

BREAST CANCER TREATMENT-RELATED CARDIOVASCULAR TOXICITY

By Audrea H. Szabatura, Pharm.D., BCOP

Introduction	225
Epidemiology and Risk Factors for CVD	225
Breast Cancer Treatment-Related Risks for CVD	226
Radiotherapy	226
Chemotherapy	226
Targeted Therapy	228
Endocrine Therapy	230
Minimizing the Risk of Treatment-Related Cardiac Effects	232
Breast Cancer Recurrence Risk Assessment	232
Role of the Pharmacist	236
Conclusion	236
Annotated Bibliography	236
Self Assessment Questions	240

DIETARY SUPPLEMENTS IN WOMEN'S AND MEN'S HEALTH

By Kelly M. Shields, Pharm.D.

Introduction	245
Menopause	246
Black Cohosh (<i>Actaea racemosa</i> , <i>Cimicifuga racemosa</i>)	246
Phytoestrogens	248
Miscellaneous Agents	248
Premenstrual Syndrome	249
Calcium	249
Magnesium	249
Pyridoxine (Vitamin B ₆)	249
Chaste Tree Berry (<i>Vitex agnus-castus</i>)	249
Evening Primrose Oil (<i>Oenothera biennis</i>)	250
Vitamin E	250
Osteoporosis	250
Dehydroepiandrosterone	250
Ipriflavone	250
Genistein	251
Benign Prostatic Hyperplasia	251
Saw Palmetto (<i>Serenoa repens</i>)	251
Pygeum (<i>Pygeum africanum</i>)	251
Beta-sitosterol	251
Rye Grass Pollen	252
Erectile Dysfunction	252
Yohimbine	252
L-Arginine	252
Dehydroepiandrosterone	252
Prostate Cancer Prevention	252
Selenium	253
Antioxidants	253
Green Tea (<i>Camellia sinensis</i>)	254
Role of the Pharmacist	254
Annotated Bibliography	254
Self Assessment Questions	258